Elsewhere, we should also see clinical and regulatory progress for the drugmaker. On the regulatory side, Vertex Pharmaceuticals expects to submit applications to the U.S. Food and Drug Administration (FDA) for zimislecel, an investigational therapy for T1D that is performing well in clinical trials . It is successfully restoring patients' ability to produce their own insulin or at least decreasing insulin dependence.Since opioid-based medications come with potentially severe side effects, we should see Jou ...